Genetic Variation in the SLC19A1 gene and Methotrexate Toxicity in Rheumatoid Arthritis Patients

We investigated the clinical relevance of SLC19A1 genetic variability for methotrexate (MTX) toxicity in rheumatoid arthritis patients using a haplotype-based approach. Two hundred and twelve unrelated rheumatoid arthritis patients and 89 lymphoblastoid cell lines were used to investigate the effect...

Full description

Saved in:
Bibliographic Details
Published inPharmacogenomics Vol. 13; no. 14; pp. 1583 - 1594
Main Authors Bohanec Grabar, Petra, Leandro-García, Luis J, Inglada-Pérez, Lucía, Logar, Dušan, Rodríguez-Antona, Cristina, Dolžan, Vita
Format Journal Article
LanguageEnglish
Published England Future Medicine Ltd 01.11.2012
Subjects
Online AccessGet full text
ISSN1462-2416
1744-8042
1744-8042
DOI10.2217/pgs.12.150

Cover

Abstract We investigated the clinical relevance of SLC19A1 genetic variability for methotrexate (MTX) toxicity in rheumatoid arthritis patients using a haplotype-based approach. Two hundred and twelve unrelated rheumatoid arthritis patients and 89 lymphoblastoid cell lines were used to investigate the effect of SLC19A1 SNPs and haplotypes on MTX adverse events and treatment discontinuation. Two putatively functional SNPs in high linkage disequilibrium, rs1051266 and rs1131596, were associated with protection (hazard ratio: 0.33; 95% CI: 0.16-0.69; adjusted p = 0.021 and hazard ratio: 0.38; 95% CI: 0.17-0.27; adjusted p = 0.021, respectively) of discontinuation of MTX treatment owing to toxicity. These SNPs were also associated with protection from infections. SLC19A1 haplotype analysis found significant associations with MTX discontinuation owing to toxicity (p = 0.025). Quantification of SLC19A1 mRNA in cell lines suggested that rs1131596 was not a major causal variant. Individual SNP and haplotype analyses suggest that rs1051266 could be a functional variant altering MTX toxicity; however, validation in independent studies is needed.
AbstractList Aim: We investigated the clinical relevance of SLC19A1 genetic variability for methotrexate (MTX) toxicity in rheumatoid arthritis patients using a haplotype-based approach. Patients & methods: Two hundred and twelve unrelated rheumatoid arthritis patients and 89 lymphoblastoid cell lines were used to investigate the effect of SLC19A1 SNPs and haplotypes on MTX adverse events and treatment discontinuation. Results: Two putatively functional SNPs in high linkage disequilibrium, rs1051266 and rs1131596, were associated with protection (hazard ratio: 0.33; 95% CI: 0.16-0.69; adjusted p = 0.021 and hazard ratio: 0.38; 95% CI: 0.17-0.27; adjusted p = 0.021, respectively) of discontinuation of MTX treatment owing to toxicity. These SNPs were also associated with protection from infections. SLC19A1 haplotype analysis found significant associations with MTX discontinuation owing to toxicity (p = 0.025). Quantification of SLC19A1 mRNA in cell lines suggested that rs1131596 was not a major causal variant. Conclusion: Individual SNP and haplotype analyses suggest that rs1051266 could be a functional variant altering MTX toxicity; however, validation in independent studies is needed. Original submitted 23 May 2012; Revision submitted 3 September 2012
We investigated the clinical relevance of SLC19A1 genetic variability for methotrexate (MTX) toxicity in rheumatoid arthritis patients using a haplotype-based approach.AIMWe investigated the clinical relevance of SLC19A1 genetic variability for methotrexate (MTX) toxicity in rheumatoid arthritis patients using a haplotype-based approach.Two hundred and twelve unrelated rheumatoid arthritis patients and 89 lymphoblastoid cell lines were used to investigate the effect of SLC19A1 SNPs and haplotypes on MTX adverse events and treatment discontinuation.PATIENTS & METHODSTwo hundred and twelve unrelated rheumatoid arthritis patients and 89 lymphoblastoid cell lines were used to investigate the effect of SLC19A1 SNPs and haplotypes on MTX adverse events and treatment discontinuation.Two putatively functional SNPs in high linkage disequilibrium, rs1051266 and rs1131596, were associated with protection (hazard ratio: 0.33; 95% CI: 0.16-0.69; adjusted p = 0.021 and hazard ratio: 0.38; 95% CI: 0.17-0.27; adjusted p = 0.021, respectively) of discontinuation of MTX treatment owing to toxicity. These SNPs were also associated with protection from infections. SLC19A1 haplotype analysis found significant associations with MTX discontinuation owing to toxicity (p = 0.025). Quantification of SLC19A1 mRNA in cell lines suggested that rs1131596 was not a major causal variant.RESULTSTwo putatively functional SNPs in high linkage disequilibrium, rs1051266 and rs1131596, were associated with protection (hazard ratio: 0.33; 95% CI: 0.16-0.69; adjusted p = 0.021 and hazard ratio: 0.38; 95% CI: 0.17-0.27; adjusted p = 0.021, respectively) of discontinuation of MTX treatment owing to toxicity. These SNPs were also associated with protection from infections. SLC19A1 haplotype analysis found significant associations with MTX discontinuation owing to toxicity (p = 0.025). Quantification of SLC19A1 mRNA in cell lines suggested that rs1131596 was not a major causal variant.Individual SNP and haplotype analyses suggest that rs1051266 could be a functional variant altering MTX toxicity; however, validation in independent studies is needed.CONCLUSIONIndividual SNP and haplotype analyses suggest that rs1051266 could be a functional variant altering MTX toxicity; however, validation in independent studies is needed.
Original submitted 23 May 2012; Revision submitted 3 September 2012
We investigated the clinical relevance of SLC19A1 genetic variability for methotrexate (MTX) toxicity in rheumatoid arthritis patients using a haplotype-based approach. Two hundred and twelve unrelated rheumatoid arthritis patients and 89 lymphoblastoid cell lines were used to investigate the effect of SLC19A1 SNPs and haplotypes on MTX adverse events and treatment discontinuation. Two putatively functional SNPs in high linkage disequilibrium, rs1051266 and rs1131596, were associated with protection (hazard ratio: 0.33; 95% CI: 0.16-0.69; adjusted p = 0.021 and hazard ratio: 0.38; 95% CI: 0.17-0.27; adjusted p = 0.021, respectively) of discontinuation of MTX treatment owing to toxicity. These SNPs were also associated with protection from infections. SLC19A1 haplotype analysis found significant associations with MTX discontinuation owing to toxicity (p = 0.025). Quantification of SLC19A1 mRNA in cell lines suggested that rs1131596 was not a major causal variant. Individual SNP and haplotype analyses suggest that rs1051266 could be a functional variant altering MTX toxicity; however, validation in independent studies is needed.
Audience Academic
Author Inglada-Pérez, Lucía
Logar, Dušan
Rodríguez-Antona, Cristina
Bohanec Grabar, Petra
Dolžan, Vita
Leandro-García, Luis J
Author_xml – sequence: 1
  givenname: Petra
  surname: Bohanec Grabar
  fullname: Bohanec Grabar, Petra
  organization: Pharmacogenetics Laboratory, Institute of Biochemistry, University of Ljubljana, Vrazov trg 2, 1000Ljubljana, Slovenia
– sequence: 2
  givenname: Luis J
  surname: Leandro-García
  fullname: Leandro-García, Luis J
  organization: Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Center, Madrid, Spain
– sequence: 3
  givenname: Lucía
  surname: Inglada-Pérez
  fullname: Inglada-Pérez, Lucía
  organization: Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Center, Madrid, Spain, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
– sequence: 4
  givenname: Dušan
  surname: Logar
  fullname: Logar, Dušan
  organization: Department of Rheumatology, University Medical Centre Ljubljana, Vodnikova 62, Ljubljana, Slovenia
– sequence: 5
  givenname: Cristina
  surname: Rodríguez-Antona
  fullname: Rodríguez-Antona, Cristina
  organization: Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, Spanish National Cancer Center, Madrid, Spain, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
– sequence: 6
  givenname: Vita
  surname: Dolžan
  fullname: Dolžan, Vita
  organization: Pharmacogenetics Laboratory, Institute of Biochemistry, University of Ljubljana, Vrazov trg 2, 1000Ljubljana, Slovenia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23148635$$D View this record in MEDLINE/PubMed
BookMark eNqN0ltrFDEUAOAgFXvRF3-ABHwpwqw5ucxkHpfFVmGlRauvMTOT2U2ZyaxJBtp_71lbFUtByUNC8uXkcs4xOQhTcIS8BLbgHKq3u01aAF-AYk_IEVRSFppJfoBjWfKCSygPyXFK14xxKCV7Rg65AKlLoY7It3MXXPYt_Wqjt9lPgfpA89bRz-sV1EugGwTUho5-dHk75ehubHb0arrxrc-3e_1p6-bR5sl3dBnzNvrsE73EYC7k9Jw87e2Q3Iv7_oR8OXt3tXpfrC_OP6yW66KVUufC9lzYRkHV9Ax72SlXa91qCayy2lred7jeibqvlGx6XTeibFQDWne8VcKKE3J6F3cXp--zS9mMPrVuGGxw05wMCK4VCC3Vf1ImoPw3hQp0BSWXSF8_oNfTHAO-GRU-rJZ1Xf5RGzs440OPP2rbfVCzFExzIYSuUC0eUdg6N_oWs997nP9rw6v7w-dmdJ3ZRT_aeGt-JRrBmzvQximl6PrfBJjZV5HBKjLADVYRYvYAY6p_Fgdeww-PbfkB0F_GRw
CitedBy_id crossref_primary_10_1080_17460441_2020_1682992
crossref_primary_10_1111_cts_70136
crossref_primary_10_2217_pgs_14_116
crossref_primary_10_1016_j_gpb_2016_11_003
crossref_primary_10_1515_raon_2017_0040
crossref_primary_10_3389_fphar_2018_00020
crossref_primary_10_1517_17425255_2016_1121233
crossref_primary_10_1080_17425255_2020_1777279
crossref_primary_10_1093_toxsci_kfu162
crossref_primary_10_1002_mgg3_884
crossref_primary_10_2217_pgs_2016_0158
crossref_primary_10_3390_diagnostics12071560
crossref_primary_10_2217_pgs_2016_0067
crossref_primary_10_1007_s00280_022_04405_7
crossref_primary_10_1038_tpj_2016_36
crossref_primary_10_2217_pgs_14_25
crossref_primary_10_2217_pgs_13_244
crossref_primary_10_3390_cimb46100685
crossref_primary_10_1016_j_intimp_2016_05_012
crossref_primary_10_1016_j_lfs_2020_118907
crossref_primary_10_3390_ijms160613760
crossref_primary_10_1007_s12026_014_8564_6
crossref_primary_10_1111_cge_13186
crossref_primary_10_1007_s00439_019_02081_x
Cites_doi 10.1002/art.21573
10.1186/1471-2105-9-557
10.1038/sj.tpj.6500438
10.1093/rheumatology/41.12.1367
10.1200/JCO.2008.20.4156
10.1006/mgme.2000.3034
10.1186/1477-7525-1-20
10.1038/ng1001-233
10.1002/art.20460
10.1038/tpj.2012.7
10.1006/meth.2001.1262
10.1007/s00228-008-0521-7
10.1159/000180580
10.1093/bioinformatics/bth457
10.1007/s00296-007-0339-0
10.1097/FPC.0b013e32833315d1
10.1002/1529-0131(200111)44:11<2525::AID-ART432>3.0.CO;2-B
10.1186/ar419
10.1093/nar/16.3.1215
10.1097/00008571-200204000-00002
10.1042/bj20020512
10.1093/rheumatology/39.9.975
10.1002/art.21726
10.1002/art.22129
10.1097/01.fpc.0000236326.80809.b1
10.1136/ard.2009.111567
10.1002/art.1780310302
10.1023/B:SCAM.0000007117.50428.63
10.1136/ard.59.suppl_1.i28
ContentType Journal Article
Copyright COPYRIGHT 2012 Future Medicine Ltd.
2012 Future Medicine Ltd
Copyright_xml – notice: COPYRIGHT 2012 Future Medicine Ltd.
– notice: 2012 Future Medicine Ltd
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8AO
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
EHMNL
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
8FD
FR3
P64
RC3
7U7
C1K
DOI 10.2217/pgs.12.150
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
UK & Ireland Database (ProQuest)
Proquest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni)
Medical Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
Technology Research Database
Engineering Research Database
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
UK & Ireland Database
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
Genetics Abstracts
Engineering Research Database
Technology Research Database
Biotechnology and BioEngineering Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
DatabaseTitleList
MEDLINE - Academic
ProQuest Central Student

Genetics Abstracts
Genetics Abstracts
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1744-8042
EndPage 1594
ExternalDocumentID 2815046481
A308233387
23148635
10_2217_pgs_12_150
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Slovenia
Spain
GeographicLocations_xml – name: Slovenia
– name: Spain
GroupedDBID ---
0R~
0VX
123
29O
4.4
53G
70G
7X7
88E
8AO
8FE
8FH
8FI
8FJ
AAWFG
AAYOK
AAYXX
ABJNI
ABUWG
ACGFS
ACPRK
ACWKX
ADBBV
AENEX
AFFYO
AFKRA
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BBNVY
BENPR
BHPHI
BPHCQ
BVXVI
CCPQU
CITATION
CS3
DU5
EBS
EHMNL
EJD
F5P
FYUFA
H13
HCIFZ
HMCUK
HZ~
IAO
IEA
IHR
ITC
LK8
M1P
M4Z
M7P
MV1
NTCAX
O9-
OVD
P2P
PHGZM
PHGZT
PQQKQ
PROAC
PSQYO
RPM
TDBHL
TEORI
TFL
TFMDE
TMEDX
UKHRP
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
3V.
7XB
8FK
ABNDM
AZQEC
DWQXO
GNUQQ
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
7X8
PUEGO
8FD
FR3
P64
RC3
7U7
C1K
ID FETCH-LOGICAL-c448t-af23ab517bf0ab54d5e988c84107a8aa2fd3abd39f754bf89b36b5b188d2c53a3
IEDL.DBID 7X7
ISSN 1462-2416
1744-8042
IngestDate Fri Sep 05 03:38:19 EDT 2025
Thu Sep 04 23:32:39 EDT 2025
Thu Sep 04 19:47:50 EDT 2025
Fri Jul 25 18:57:39 EDT 2025
Tue Jun 17 21:25:01 EDT 2025
Tue Jun 10 20:30:12 EDT 2025
Thu Apr 03 06:53:48 EDT 2025
Tue Jul 01 01:07:49 EDT 2025
Thu Apr 24 23:14:41 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 14
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c448t-af23ab517bf0ab54d5e988c84107a8aa2fd3abd39f754bf89b36b5b188d2c53a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
PMID 23148635
PQID 1151794996
PQPubID 23462
PageCount 12
ParticipantIDs proquest_miscellaneous_1328513845
proquest_miscellaneous_1328510316
proquest_miscellaneous_1171871624
proquest_journals_1151794996
gale_infotracmisc_A308233387
gale_infotracacademiconefile_A308233387
pubmed_primary_23148635
crossref_primary_10_2217_pgs_12_150
crossref_citationtrail_10_2217_pgs_12_150
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2012-11-00
2012-Nov
20121101
PublicationDateYYYYMMDD 2012-11-01
PublicationDate_xml – month: 11
  year: 2012
  text: 2012-11-00
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Pharmacogenomics
PublicationTitleAlternate Pharmacogenomics
PublicationYear 2012
Publisher Future Medicine Ltd
Publisher_xml – name: Future Medicine Ltd
References e_1_3_4_3_17_1
e_1_3_4_3_16_1
e_1_3_4_3_15_1
e_1_3_4_3_14_1
e_1_3_4_3_19_1
e_1_3_4_3_18_1
e_1_3_4_3_21_1
e_1_3_4_3_22_1
e_1_3_4_3_9_1
e_1_3_4_3_23_1
e_1_3_4_3_24_1
James HM (e_1_3_4_3_27_1) 2008; 35
e_1_3_4_3_20_1
e_1_3_4_4_2_1
e_1_3_4_4_3_1
Takatori R (e_1_3_4_3_28_1) 2006; 24
Berkun Y (e_1_3_4_3_10_1) 2007; 34
e_1_3_4_3_2_1
e_1_3_4_3_29_1
e_1_3_4_3_1_1
e_1_3_4_3_4_1
e_1_3_4_3_3_1
e_1_3_4_3_7_1
e_1_3_4_3_25_1
e_1_3_4_3_8_1
e_1_3_4_3_26_1
e_1_3_4_3_5_1
e_1_3_4_3_6_1
e_1_3_4_3_32_1
e_1_3_4_3_33_1
e_1_3_4_3_34_1
e_1_3_4_3_13_1
e_1_3_4_3_12_1
e_1_3_4_3_11_1
e_1_3_4_3_30_1
e_1_3_4_3_31_1
References_xml – ident: e_1_3_4_4_3_1
– ident: e_1_3_4_3_7_1
  doi: 10.1002/art.21573
– ident: e_1_3_4_3_25_1
  doi: 10.1186/1471-2105-9-557
– ident: e_1_3_4_3_11_1
  doi: 10.1038/sj.tpj.6500438
– ident: e_1_3_4_3_2_1
  doi: 10.1093/rheumatology/41.12.1367
– ident: e_1_3_4_3_32_1
  doi: 10.1200/JCO.2008.20.4156
– ident: e_1_3_4_3_21_1
  doi: 10.1006/mgme.2000.3034
– ident: e_1_3_4_3_19_1
  doi: 10.1186/1477-7525-1-20
– ident: e_1_3_4_3_16_1
  doi: 10.1038/ng1001-233
– ident: e_1_3_4_3_26_1
  doi: 10.1002/art.20460
– ident: e_1_3_4_3_14_1
  doi: 10.1038/tpj.2012.7
– ident: e_1_3_4_3_24_1
  doi: 10.1006/meth.2001.1262
– ident: e_1_3_4_3_12_1
  doi: 10.1007/s00228-008-0521-7
– ident: e_1_3_4_3_20_1
  doi: 10.1159/000180580
– ident: e_1_3_4_4_2_1
– ident: e_1_3_4_3_22_1
  doi: 10.1093/bioinformatics/bth457
– ident: e_1_3_4_3_15_1
  doi: 10.1007/s00296-007-0339-0
– volume: 35
  start-page: 562
  issue: 4
  year: 2008
  ident: e_1_3_4_3_27_1
  article-title: Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
  publication-title: J. Rheumatol.
– ident: e_1_3_4_3_29_1
  doi: 10.1097/FPC.0b013e32833315d1
– ident: e_1_3_4_3_6_1
  doi: 10.1002/1529-0131(200111)44:11<2525::AID-ART432>3.0.CO;2-B
– ident: e_1_3_4_3_1_1
  doi: 10.1186/ar419
– ident: e_1_3_4_3_23_1
  doi: 10.1093/nar/16.3.1215
– ident: e_1_3_4_3_5_1
  doi: 10.1097/00008571-200204000-00002
– ident: e_1_3_4_3_31_1
  doi: 10.1042/bj20020512
– ident: e_1_3_4_3_3_1
  doi: 10.1093/rheumatology/39.9.975
– ident: e_1_3_4_3_8_1
  doi: 10.1002/art.21726
– ident: e_1_3_4_3_33_1
– ident: e_1_3_4_3_9_1
  doi: 10.1002/art.22129
– ident: e_1_3_4_3_4_1
  doi: 10.1097/01.fpc.0000236326.80809.b1
– ident: e_1_3_4_3_13_1
  doi: 10.1136/ard.2009.111567
– ident: e_1_3_4_3_17_1
  doi: 10.1002/art.1780310302
– ident: e_1_3_4_3_30_1
  doi: 10.1023/B:SCAM.0000007117.50428.63
– volume: 24
  start-page: 546
  issue: 5
  year: 2006
  ident: e_1_3_4_3_28_1
  publication-title: Clin. Exp. Rheumatol.
– ident: e_1_3_4_3_34_1
– volume: 34
  start-page: 1664
  issue: 8
  year: 2007
  ident: e_1_3_4_3_10_1
  publication-title: J. Rheumatol.
– ident: e_1_3_4_3_18_1
  doi: 10.1136/ard.59.suppl_1.i28
SSID ssj0021640
Score 2.15871
SecondaryResourceType review_article
Snippet We investigated the clinical relevance of SLC19A1 genetic variability for methotrexate (MTX) toxicity in rheumatoid arthritis patients using a haplotype-based...
Aim: We investigated the clinical relevance of SLC19A1 genetic variability for methotrexate (MTX) toxicity in rheumatoid arthritis patients using a...
Original submitted 23 May 2012; Revision submitted 3 September 2012
SourceID proquest
gale
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 1583
SubjectTerms Aged
Analysis
Antirheumatic Agents - administration & dosage
Antirheumatic Agents - toxicity
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - genetics
Biomarkers, Pharmacological
Cell Line
Drug therapy
Drugs
Female
Genetic aspects
Genetic Association Studies
Haplotypes
Health aspects
Humans
Linkage Disequilibrium
Male
Methotrexate
Methotrexate - administration & dosage
Methotrexate - toxicity
Middle Aged
Polymorphism, Single Nucleotide
Reduced Folate Carrier Protein - genetics
Rheumatoid arthritis
Single nucleotide polymorphisms
Title Genetic Variation in the SLC19A1 gene and Methotrexate Toxicity in Rheumatoid Arthritis Patients
URI https://www.ncbi.nlm.nih.gov/pubmed/23148635
https://www.proquest.com/docview/1151794996
https://www.proquest.com/docview/1171871624
https://www.proquest.com/docview/1328510316
https://www.proquest.com/docview/1328513845
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED_B9sIL4puwMRmBhpAWrf5I4jyhMm2aEEwVbFLfgmM7WyWUlDadtv-eOydt2YT65AdfHMd3tn_n-H4H8EE74XW4qqNkCMlJYs0THcvUWu7RP8gCqc_3s_T0Qn0dJ-P-wG3eX6tcrolhoXaNpTPyQ0QuZDsIzz9P_8SUNYr-rvYpNB7CNkckQqkbsvHa4UJXYNBFF4kYd6q0oycViMIPp5dzOgbkFG__z4Z0f1m-BzbDpnPyBB73aJENO_U-hQe-fgb7o45u-vaAna-jp-YHbJ-N1kTUt8_hF3FKYxW7Roc4aIBNaoaIj_38dsTzIWdoPZ6Z2rGQSLqd-RuEnqxtbiYW0TlJz678AkFtM3EMjewqUCCxnox1_gIuTo7Pj07jPqNCbNENa2NTCWlKHMiyGmCpXOJzra1W6AQabYyoHNY7mVdZospK56VMy6TkGlVqE2nkS9iqm9q_BmYMd8o6UfrMqDTFkpuBTdPcIWLwAxHBp-WwFranG6esF78LdDtIBQWqoOCiQBVE8H4lO-1INv4r9ZG0U9DMw5as6QMIsD_EYVUMA_MOutxZBLt3JHHG2LvVS_0W_YzFd6zsK4J3q2p6km6h1b5ZkAzu5ES5pTbISKGJpZBvaifISK2SCF519rX6bsTbSiMKfLO5kzvwCKGb6KIid2GrnS38W4RHbbkX5sAebH85Phv9-AvK2A8s
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4a3QO8IO6EDTAChpAWrXac1HmYUBmbOtZVFXTS3jLHdlilKSm9wPrn-G0cO5exCfVtT3nwqZvkHNvf5_h8B-Cd0MwId1SHBy4lJ_QFDYUfREpRg_yg40R9jgdR74R_PQ1P1-BPnQtjj1XWc6KbqHWh7B75DiIXGzsIzz9Nfvq2apT9ulqX0JBVaQW96yTGqsSOI7P8jRRutnv4Bf39nrGD_dFez6-qDPgKqcnclxkLZIqdp1kbr1yHJhZCCY7ESAopWaaxXQdx1gl5mok4DaI0TKnAx1RhIAPs9w6sc7uB0oL1z_uD4beG8iEZaZf5TczHtTIqBVIZ8oCdyY-Z3YikNuP_nyXx5sJwA-66Ze_gAdyv8CrplgH2ENZM_gi2hqXg9XKbjK7yt2bbZIsMr6Swl4_hzKpaYxP5hZTcxQAZ5wQxJ_ne36NxlxKMX0NkrokrZT2fmksEv2ReXI4V8gNrPT03C4TVxVgTDPNzJ8JEKjnY2RM4uZW3_RRaeZGb50CkpJorzVLTkTyK8EplW0VRrBGzmDbz4GP9WhNVCZ7buhsXCRIf64IEXZBQlqALPHjb2E5KmY__Wn2w3kns2MeelKxSGPB-rIpW0nXaP0j6Ox5sXrPEMauuN9f-Tao5A_-jiXAP3jTN9pf2HFxuioW1QSxhRb_4CpuACauTSFf142wCwUMPnpXx1Tw3In4uEIe-WH2Tr-Fub3TcT_qHg6MNuIdAkpU5mpvQmk8X5iWCtXn6qhoRBM5uexD-BRzWUlQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4aQ0K8IO4LDDAChpAWtb4kcR4QqjaqjY2pEpvUt8yxHVYJJaVNYf1r_DqOnbRlE-rbnvLgE-dyju3vS3y-A_BWGmal36ojuE_JiUJJIxnyWGtqkR8kXtTn60l8cCa-DKPhBvxZ5MK4bZWLOdFP1KbS7ht5B5GLix2E552i3RYx2O9_Gv8MXQUp96d1UU6jCZEjO_-N9G368XAfff2Osf7n072DsK0wEGqkJXWoCsZVjh3nRRePwkQ2lVJLgaRISaVYYbDd8LRIIpEXMs15nEc5lfiIOuKKY7-34HbChXBlI5LhiuwhDek2mU0sxFUybqRRGTKAzvj71H2CpC7X_5_F8PqScA3o-gWvfx_utUiV9JrQegAbtnwIO4NG6nq-S05XmVvTXbJDBisR7PkjOHd61thEfiEZ994no5Ig2iTfjvdo2qMEI9cSVRrii1jXE3uJsJfU1eVIIzNw1pMLO0NAXY0MwQC_8PJLpBWCnT6Gsxt5109gs6xKuwVEKWqENiy3iRJxjEequjqOU4NoxXZZAB8WrzXTrdS5q7jxI0PK41yQoQsyyjJ0QQBvlrbjRuDjv1bvnXcyN-qxJ63a5AW8H6eflfW86g_S_SSA7SuWOFr11eaFf7N2tsBrLGM7gNfLZnem2wFX2mrmbBBFOLkvscaGM-kUEum6frwNlyIK4GkTX8vnRqwvJCLQZ-tv8hXcwaGXHR-eHD2Hu4ggWZOcuQ2b9WRmXyBKq_OXfjgQOL_p8fcX635P8A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genetic+variation+in+the+SLC19A1+gene+and+methotrexate+toxicity+in+rheumatoid+arthritis+patients&rft.jtitle=Pharmacogenomics&rft.au=Bohanec+Grabar%2C+Petra&rft.au=Leandro-Garc%C3%ADa%2C+Luis+J&rft.au=Inglada-P%C3%A9rez%2C+Luc%C3%ADa&rft.au=Logar%2C+Du%C5%A1an&rft.date=2012-11-01&rft.pub=Future+Medicine+Ltd&rft.issn=1462-2416&rft.volume=13&rft.issue=14&rft.spage=1583&rft_id=info:doi/10.2217%2Fpgs.12.150&rft.externalDocID=A308233387
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-2416&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-2416&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-2416&client=summon